Following STEMI treated with primary PCI, which P2Y12 inhibitor has shown superior mortality benefit in the PLATO trial compared to clopidogrel?

• A Prasugrel
• B Cangrelor
• C Vorapaxar
• D Ticagrelor ✓

Explanation

The PLATO trial (NEJM 2009) demonstrated that ticagrelor significantly reduced the composite of vascular death, MI, and stroke compared to clopidogrel in ACS patients, including a significant mortality reduction. Ticagrelor is a direct-acting reversible P2Y12 inhibitor. Prasugrel showed benefit in TRITON-TIMI 38 but specifically in PCI-treated patients without prior stroke/TIA. Cangrelor is an IV agent; vorapaxar is a PAR-1 inhibitor.

Reference: Harrison's Principles of Internal Medicine, 21st ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.